Study of two drug combos for PD-L1 positive advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—sacituzumab govitecan and toripalimab—against another combination (toripalimab plus nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see which combination works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is triple-negative and has spread to other parts of the body or cannot be removed with surgery.
- Your tumor is PD-L1 positive (a protein score of 1 or higher).
- You have not had any previous treatment for advanced triple-negative breast cancer.
- Your cancer can be measured on scans, and you are in good general health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 trial tests two different drug combinations given in an alternating pattern for people with advanced triple-negative breast cancer that is HER2-low. The goal is to see if this approach is safe and effective.
This study tests a combination of two investigational drugs—sacituzumab govitecan and a CDK7 inhibitor—in people with advanced triple-negative breast cancer who have already tried several treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests a new combination of two drugs (Sac-TMT and Toripalimab) as the first treatment for women with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see if this combination can shrink or control the cancer better than standard treatments.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Hear when a new Triple Negative Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.